This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Ethyol

Cumberland Pharmaceuticals Inc.

Drug Names(s): Amifostine

Description: The active ingredient of Ethyol, amifostine, is an aminothiol that is thought to have cytoprotective effects through various mechanisms.It binds to platinums and alkylating agents; it scavenges free radicals that can damage cells; and it upregulates p53 thereby reducing apoptosis.

Deal Structure: Scherico is the exclusive distribution partner for Ethyol in the countries comprising the European Territories. Scherico and other affiliates of Schering have various other licensing and distribution arrangements for Ethyol and NeuTrexin outside of the United States.

Since October 1, 2001, MedImmune has been the sole marketer of Ethyol in the United States. Prior to this date, Ethyol was co-promoted by MedImmune and ALZA Corporation (ALZA). Outside the United States, the Company has various distribution and marketing arrangements for Ethyol, primarily with affiliates of Schering-Plough Corporation (Schering). The product has been approved in 60 countries worldwide.

The Company acquired U.S. marketing rights to Ethyol from ALZA, effective October 1, 2001. Previously, ALZA was responsible for sales and marketing of Ethyol in the U.S. under a December 1995 co-promotion agreement between the two companies. In accordance with the original agreement, MedImmune Oncology will...See full deal structure in Biomedtracker

Partners: Johnson & Johnson Merck & Co., Inc. AstraZeneca PLC Clinigen Group plc


Ethyol News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug